Skip to content

MassBio

Massachusetts Biotechnology Council

Open search form
  • Sign In/Create Account
  • Pay Company Dues
  • Become a Member
  • Resources
    • 2023 Industry Snapshot
    • 2022 Massachusetts Biopharma Funding Report
    • 2022 MA Life Sciences Workforce Analysis Report
    • 2021 State of Diversity, Equity, & Inclusion Report
    • Economic Development
    • Biopharma Startup Toolkit
    • Career Center
    • MassBioEd
  • Events
    • Events Calendar
    • Overview of Events
    • Get Involved
  • Membership
    • Member Directory
    • Benefits of Membership
    • Savings and Rewards
    • Member News
    • Become a Member
    • Member Rates
    • Pay Company Dues
  • Savings & Rewards
    • MassBioEdge
  • Conference Center
    • MassBioHub
  • Programs
    • Bioversity at Southline Boston
    • State of Possible 2025 Report
    • Diversity, Equity, and Inclusion
    • Policy & Advocacy
    • Partnering Opportunities
    • MassBioDrive
    • Digital Health
    • BioReady Communities
  • About Us
    • About Us
    • News & Thought Leadership
    • Sponsorship Opportunities
    • Staff
    • Board of Directors
    • FAQs
    • Contact Us
  • Sign In/Create Account
  • Pay Company Dues
  • Become a Member
Open search form

Member Directory

Click to Open Main Menu

Dicerna Pharmaceuticals

Life Sciences | Drug Development
Lexington, MA (617) 621-8097 Website @DicernaPharma

Overview

Dicerna Technology: Next Generation RNAi and RNAi Delivery

Dicerna is a leading developer of RNAi drugs targeting unmet needs in cancer. The company’s novel Dicer Substrate siRNA (DsiRNA) molecules and proprietary drug delivery technologies have the demonstrated ability to silence previously undruggable disease targets. Dicerna’s RNAi platform is comprised of two key components: Dicer Substrates (DsiRNAs), which are 25-30 asymmetric double stranded RNAs that mediate RNAi with extremely high potency, and EnCore lipid nanoparticles, which are optimized for tumor delivery of RNAi molecules. The DsiRNA platform is broadly covered by the recently issued US patent 8,084,599.

Based in Watertown, the company currently employs 28 professionals and is backed by a strong syndicate of venture firms: Abingworth, Domain, Oxford, Skyline, and SR One.

See all Members

Massachusetts Biotechnology Council

700 Technology Square, 5th Floor
Cambridge, MA 02139
617.674.5100

  • Contact
  • Privacy Policy
  • Fulfillment Policy
  • © 2023 All Rights Reserved